MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Mon Feb 19 00:00:00 GMT-05:00 2024
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Download
Mon Jan 29 00:00:00 GMT-05:00 2024
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Download
Wed Jan 17 00:00:00 GMT-05:00 2024
U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen
Download
Fri Dec 22 00:00:00 GMT-05:00 2023
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Download
Mon Dec 18 00:00:00 GMT-05:00 2023
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
Download
Fri Dec 01 00:00:00 GMT-05:00 2023
Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH
Download
Mon Oct 23 00:00:00 GMT-05:00 2023
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Download
Mon Oct 23 00:00:00 GMT-05:00 2023
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Download
Mon Oct 23 00:00:00 GMT-05:00 2023
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Download
Sun Oct 22 00:00:00 GMT-05:00 2023
Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
Download